IBRX Immunitybio Inc
Company Analysis
Latest News
🔴 Immunitybio is trading 4.37% down today as broader biotech weakness reverses sector rally
Immunitybio is trading 4.37% down now at $7.78 after broader biotech weakness reversed the sector’s previous-session rally. - No fresh company-specific...
🟢 Immunitybio is trading 5.6% up today on biotech-sector strength
Immunitybio is trading at $8.15, up 5.63%, as strength across the biotechnology sector lifts sentiment. - XBI is up 3.73% during regular trading after...
🟢 Immunitybio is trading 4.4% up in pre-market as biotech ETF XBI rises 2.27%
Immunitybio is trading at $8.06 (+4.40%), primarily on biotech-sector strength. - Biotech ETF XBI is up 2.27% pre-market after positive Merck-Moderna...
🔴 Immunitybio is trading 4.42% down today as U.S. markets weaken
Immunitybio is trading 4.42% down now at $7.57 as U.S. markets weaken. - The S&P 500 is down 0.58%, while the Nasdaq Composite is down 1.36%. - The broader...
Goldman Sachs Holds $28M ImmunityBio Stake, Eyeing Cancer Drug Catalysts
Goldman Sachs disclosed a $28.32 million holding in ImmunityBio. The position includes 3.23 million shares. This holding remained nearly unchanged from the...
🟢 Immunitybio is trading 4.03% up today with no clear company-specific catalyst
Immunitybio is trading 4.03% up at $7.88, with no clear company-specific catalyst identified for August 17, 2026. - Its investor-relations page lists the...
ImmunityBio Appoints Former World Bank President Jim Yong Kim, Targeting Global Expansion
ImmunityBio appointed Dr. Jim Yong Kim as Vice Chairman. Dr. Kim served as the twelfth president of the World Bank Group from 2012 to 2019. He will focus on...
🟢 Immunitybio is trading 4.3% up today after Q2 revenue surges 92% YoY
Immunitybio is trading at $7.25 (+4.32%) after reporting second-quarter product revenue of $50.7 million, representing a 92% year-over-year increase. • The...
🔴 Immunitybio is trading 5.2% down today as wider Q2 net loss offsets strong ANKTIVA revenue growth
Immunitybio is trading 5.2% down now at $6.76 after releasing Q2 earnings that showed a wider GAAP net loss per share, primarily driven by non-cash fair value...
ImmunityBio's second quarter product revenue of $50.7M surges 92%, easily beating estimates, while net loss widens.
ImmunityBio reported second quarter 2026 net product revenue of $50.7 million, a 92% increase year-over-year, marking the eighth consecutive quarter of...
Immunitybio Inc Q2 2026 Earnings Preview: What Analysts Expect on August 04, 2026
ImmunityBio is expected to report a Q2 2026 loss of $0.09 per share on revenue of $18.50 million, while the current stock price of $7.45 remains significantly...
🔴 Immunitybio is trading 4.4% down today amid broader biotech sector weakness
Immunitybio is trading at $7.12 (-4.43%) as the stock pulls back from its recent rally, tracking broader weakness across the biotechnology sector. • The...
ImmunityBio's ANKTIVA® Receives UAE Marketing Authorization for Bladder and Lung Cancer
ImmunityBio announced it has received marketing authorization from the United Arab Emirates (UAE) Emirates Drug Establishment (EDE) for its drug ANKTIVA® for...
ImmunityBio Rallies 8%, Securing Broadest Global Anktiva Approval in UAE
ImmunityBio (IBRX) shares rose nearly 8% after the United Arab Emirates (UAE) granted marketing authorization for its cancer immunotherapy, Anktiva. The...
🟢 Immunitybio is trading 4.2% up today on technical rebound and broader market strength
Immunitybio is trading 4.2% up at $7.08 on a technical rebound following several weak sessions and a sharp move higher after-hours on July 29. • The advance...
🟢 Immunitybio is trading 5.2% up today, rebounding from recent weakness without a clear catalyst
Immunitybio is trading at $7.19 (5.2% up) in pre-market, rebounding from recent weakness following a strong after-hours move on July 29. • The move appears to...
🟢 Immunitybio is trading 7.3% up today, rebounding in after-hours despite no clear catalyst
Immunitybio is trading 7.3% up at $7.33 in after-hours sessions, rebounding from recent weakness despite a lack of fresh company-specific news. • No earnings...
🔴 Immunitybio is trading 4.1% down today, underperforming a bullish biotech sector
Immunitybio is trading at $6.71 (down 4.1%), underperforming a biotech sector that is currently up over 2% on M&A-driven optimism. • The move lacks a clearly...
🔴 Immunitybio is trading 4.3% down today as shares consolidate without fresh catalysts
Immunitybio is trading at $7.08, down 4.3% today as the stock appears to be consolidating following recent volatility and a lack of new company-specific...
🔴 Immunitybio is trading 5.0% down
Immunitybio is trading at $7.66, down 5.0% from a comparison close of $8.07 during regular trading. This is a price-action follow-up, so a separate catalyst...